When does MEDIPHARM LABS CORP (LABS.CA) report earnings?
MEDIPHARM LABS CORP (LABS.CA) will report earnings on 2026-05-12.
MEDIPHARM LABS CORP (LABS.CA) Forecast, Price Target & Analyst Ratings
TSX:LABS • CA58504D1006
Current stock price
0.065 CAD
0 (0%)
Last:
Analyst forecast overview
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for MEDIPHARM LABS CORP (LABS.CA).
Forecast Snapshot
Next Earnings Forecast
Earnings Estimate- Release Date
- May 12, 2026
- Period
- Q1 / 2026
- EPS Estimate
- CA$0.00
- Revenue Estimate
- 8.871M
Price Target Details & History
Consensus Price Target and Range
Mean target
N/A
Upside
N/A
From current price of CA$0.07 to mean target of N/A, Based on 9 analyst forecasts
Low
N/A
Median
N/A
High
N/A
Price Target Revisions
1 Month
0.00%
3 Months
0.00%
Price Target Summary
Analyst Ratings & History
Current Analyst Ratings
Analyst Ratings History
Analyst Ratings Consensus
ChartMill Buy Consensus
42.22%
LABS.CA was analyzed by 9 analysts. The buy percentage consensus is at 42. So analysts seem to be rather negative about LABS.CA.
In the previous month the buy percentage consensus was at a similar level.
LABS.CA was analyzed by 9 analysts. More opinions would make the average more meaningful.
Recent Upgrades & Downgrades
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2022-04-04 | Canaccord Capital | Downgrade | Hold |
| 2022-04-04 | Alliance Global Partners | Downgrade | Buy |
| 2021-11-16 | CanaccordFinancial | Downgrade | Hold |
| 2021-08-17 | Alliance Global Partners | Downgrade | Strong Buy |
| 2021-08-17 | Canaccord Genuity | Downgrade | Buy |
Next Earnings Forecast Details
Next Earnings Details
- Release Date
- May 12, 2026
- Period
- Q1 / 2026
- EPS Estimate
- CA$0.00
- Revenue Estimate
- 8.871M
- Revenue Q2Q
- -17.91%
- EPS Q2Q
- -206.00%
- Number of Analysts
- 3
Next Earnings Revisions
Revenue (1 Month)
N/A
Revenue (3 Months)
N/A
EPS (1 Month)
N/A
EPS (3 Months)
N/A
Next Earnings Summary
LABS.CA is expected to report earnings on 5/12/2026. The consensus EPS estimate for the next earnings is 0 CAD and the consensus revenue estimate is 8.87M CAD.
Full Analyst Estimates 2026 - 2027
Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates
| 2023 | 2024 | 2025 | 2026 | 2027 | ||
|---|---|---|---|---|---|---|
| Revenue YoY % growth | 33.062M 49.60% | 41.961M 26.92% | 45.124M 7.54% | 39.762M -11.88% | 45.168M 13.60% | |
| EBITDA YoY % growth | -17.098M 35.06% | -9.039M 47.13% | -8.62M 4.64% | -1.275M 85.21% | -144.84K 88.64% | |
| EBIT YoY % growth | -19.614M 32.83% | -11.639M 40.66% | -10.28M 11.68% | 438.6K 104.27% | N/A | |
| Operating Margin | -59.32% | -27.74% | -22.78% | 1.10% | N/A | |
| EPS YoY % growth | -0.04 63.64% | -0.04 | -0.03 35.00% | -0.01 68.62% | -0.01 12.50% |
All data in CAD
Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates
| Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | |
|---|---|---|---|---|
| EPS Q2Q % growth | 0.00 -206.00% | 0.00 69.40% | 0.00 79.60% | 0.00 79.60% |
| Revenue Q2Q % growth | 8.871M -17.91% | 9.106M -27.80% | 10.381M -15.04% | 11.405M 3.10% |
| EBITDA Q2Q % growth | -864.96K -94.37% | -592.62K 82.70% | -90.78K 93.48% | 274.38K 136.29% |
| EBIT Q2Q % growth | -1.484M -70.59% | -1.211M 71.64% | -709.92K 73.27% | -344.76K 85.73% |
All data in CAD
Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data
Long Term Forward Growth Forecast Summary
Long Term EPS Growth (CAGR)
EPS Next 3 Year
N/A
EPS Next 5 Year
N/A
Long Term Revenue Growth (CAGR)
Revenue Next 3 Year
N/A
Revenue Next 5 Year
N/A
Long Term EBIT Growth (CAGR)
EBIT Next 3 Year
N/A
EBIT Next 5 Year
N/A
MEDIPHARM LABS CORP / LABS.CA Forecast FAQ
What are the consensus estimates for LABS stock next earnings?
The consensus EPS estimate for the next earnings of MEDIPHARM LABS CORP (LABS.CA) is 0 CAD and the consensus revenue estimate is 8.87M CAD.
Can you provide the consensus rating for MEDIPHARM LABS CORP stock?
The consensus rating for MEDIPHARM LABS CORP (LABS.CA) is 42.2222 / 100 . This indicates that analysts generally have a neutral outlook on the stock.